A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs. host disease after allogenic stem cell transplantation

Type of Cancer

Phase

Division (Location)

Study ID

NCT#

Brief Description
A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs. host disease after allogenic stem cell transplantation

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.